tbuckley/cabot-search huggingface dataset:
Validation of the Response Speed Rule to Predict the Efficacy of a Therapeutic Regimen in Myeloma
Authors: Jose Enrique De La Puerta Rueda, Clara Gómez Pérez, Concepción Velado Rodriguez, Tomas Carrascosa Vallejo, Begoña Sancho Garaizabal, Maria José Ereño Ealo, Elixabete Pastor Ausin, Isabel Uriarte, Iñigo Vicente Olabarria, Alberto Cabrera Zubizarreta, José María Ontañón Garcés, Ibone Saralegui Prieto, Matxalen Olivares Salaverri, Inmaculada Barredo Santamaría, Alberto Sáiz López, Paula Arana Berganza, Natalia Maruri Machado, Raquel Pérez Garay, Eloisa Urrechaga Igartua, Ianire Etxeguren Urkixo, Garazi Letamendi Madariaga, Cristina Martínez Bilbao, Itxaso Amarika Ibarrondo, Amaia Casado Diez, Inés González Vallejo, Cristina Cortes Fernández, Eukene Gainza González, Jesus Ojanguren Bergaz, Paloma Ibarrondo Chamorro, Ane Aranbarri Chamorro, Javier Goikolea Ugarte, Miriam Bustos Martínez, Amaia Sierra Zabala, Urko Aguirre Larracoechea, Marta Alonso Varela
Journal: Blood (2020)
PU.1-Dependent Enhancer Decommissioning Drives Transformation of <i>Tet2</i> deficient Hematopoietic Stem and Progenitor Cells
Authors: Maria M. Aivalioti, Tushar D Bhagat, Aditi Paranjpe, Boris Bartholdy, Kith Pradhan, Mario Pujato, Amit Verma, Britta Will
Journal: Blood (2020)
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with<i>PIK3CA</i>-Mutant Cancers
Authors: Komal Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid Aljumaily, Philippe L. Bedard, Jasgit C. Sachdev, Lara Dunn, Helen Won, John Bond, Surai Jones, Heidi M. Savage, Maurizio Scaltriti, Timothy R. Wilson, Michael C. Wei, David M. Hyman
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Somatic mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which encodes the p110α catalytic subunit of PI3K, are found in multiple human cancers. While recurrent mutations in PIK3CA helical, regulatory, and kinase domains lead to constitutive PI3K pathway activation, other mutations remain uncharacterized. To further evaluate their clinical actionability, we designed a basket study for patients with PIK3CA-mutant cancers with the isoform-specific PI3K inhibitor taselisib. Patients and Methods: Patients were enrolled on the basis of local PIK3CA mutation testing into one of 11 histology-specific cohorts and treated with taselisib at 6 or 4 mg daily until progression. Tumor DNA from baseline and progression (when available) was sequenced using a next-generation sequencing panel. Exploratory analyses correlating genomic alterations with treatment outcomes were performed. Results: A total of 166 patients with PIK3CA-mutant cancers were enrolled. The confirmed response rate was 9%. Activity varied by tumor type and mutant allele, with confirmed responses observed in head and neck squamous (15.4%), cervical (10%), and other cancers, plus in tumors containing helical domain mutations. Genomic analyses identified mutations potentially associated with resistance to PI3K inhibition upfront (TP53 and PTEN) and postprogression through reactivation of the PI3K pathway (PTEN, STK11, and PIK3R1). Higher rates of dose modification occurred at higher doses of taselisib, indicating a narrow therapeutic index. Conclusions: Taselisib had limited activity in the tumor types tested and is no longer in development. This genome-driven study improves understanding of the activity, limitations, and resistance mechanisms of using PI3K inhibitors as monotherapy to target PIK3CA-mutant tumors.
COVID 19 and Hemoglobinopathies: Update of the Italian Experience
Authors: Irene Motta, Valeria Maria Pinto, Filomena Longo, Federico Bonetti, Elisa De Michele, Alberto Piperno, Lorella Pitrolo, Micol Quaresima, Michela Ribersani, Margherita Migone De Amicis, Manuela Balocco, Barbara Gianesin, Giovanna Graziadei, Maria Domenica Cappellini, Lucia De Franceschi, Antonio Piga, Gian Luca Forni
Journal: Blood (2020)
Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial
Authors: Christian Buske, Meletios A Dimopoulos, Alexander Grunenberg, Efstathios Kastritis, Cecile Tomowiak, Béatrice Mahé, Xavier Troussard, Roman Hajek, Andreas Viardot, Olivier Tournilhac, Therese Aurran, Stephane Lepretre, Hacene Zerazhi, Benedicte Hivert, Veronique Leblond, Sophie de Guibert, Lena Brandefors, Ramon Garcia-Sanz, Maria Gomes da Silva, Eva Kimby, Jens Dreyhaupt, Rainer Muche, Pierre Morel
Journal: Blood (2020)
Urgent Cytoreductive Chemotherapy for Newly Diagnosed Patients with AML Is Safe and Feasible and Facilitates Enrollment on Investigational Clinical Trials
Authors: Kunhwa Kim, Marina Konopleva, Courtney D. DiNardo, Gautam Borthakur, Guillermo Garcia-Manero, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Steven M. Kornblau, Musa Yilmaz, Maro Ohanian, Alessandra Ferrajoli, Nitin Jain, Nicholas J. Short, Caitlin R. Rausch, Mark Brandt, Sherry A. Pierce, Zeev E. Estrov, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia
Journal: Blood (2020)
Use of water immersion instead of water exchange underlay the unfavourable outcomes in the water-assisted sigmoidoscopy (WAS) study
Authors: Chih-Wei Tseng, Yu-Hsi Hsieh
Journal: Gut (2020)

We read with interest the study by Rutter and colleagues on the role of water-assisted sigmoidoscopy (WAS) in the English National Health Service bowel scope screening, showing that the proportion of patients reporting moderate or severe pain were comparable between WAS and CO2 technique (14% in WAS, 15% in CO2; p=0.47). The WAS group had statistically significantly lower adenoma detection rate (ADR) (11% vs 15%, p=0.03).1 Water-assisted colonoscopy consisted of two techniques distinguished by the timing of removal of infused water, predominantly during withdrawal (water immersion, WI) or during insertion (water exchange, WE) (figure 1). The authors stated that their method was water-assisted rather than full WE. However, as WI and WE have different impacts on insertion pain and ADR,2 we feel a need to comment on the insertion method used in the study. WE emphasises …
Abstract 294: Microrna-208a: A Marker of No-Reflow in STEMI Patients Undergoing Primary Percutaneuos Coronary Intervention
Authors: Abou Bakr M Salama, Wael A Khalil, MAnar M Al-Zaky, Somia H Abdallah, Nader T Kandil, Ahmed Abdelsabour, Ahmed M Shaker, Mesbah T Hasanein, Giovanni B Luciani, Hassan Azzazy
Journal: Circulation Research (2020)

Background: Biomarkers are the corner stone for diagnosis of myocardial infarction (MI). MicroRNA-208a (miR-208a) is known to be heart specific. So, this study was designed to explore its role as a marker for diagnosis of MI as well as a predictor of outcome of primary percutaneuos coronary angiography especially no-reflow phenomenon. Methods: This study was carried out between January 2018 and August 2019 in Cardiology Department, Zagazig University Hospitals, Egypt. Approval was obtained from institutional review board adhering to the guidelines of the Declaration of Helsinki. Patients (n=75) presented by chest pain were recruited into two groups. Group 1 (n=40) had STEMI and underwent primary PCI: 21 patients with sufficient reperfusion and 19 with no-reflow. Group 2 (n= 35) had negative troponin T (cTnT). Plasma miR-208a expression was assessed using quantitative polymerase chain reaction and patients were followed for occurrence of in-hospital (3 days average) major adverse cardiac events (MACE). Results: Analysis of relative expression values shows that miR-208a has reasonable sensitivity and specificity for MI diagnosis (AUC= 0.92, sensitivity = 92.5, Specificity = 80) which is comparable to the routine cardiac biomarkers; creatine kinase-MB (CK-MB) (area difference 0.0439, P= 0.235) and cTnT (area difference 0.0614, P= 0.06). The no-reflow group (b) had higher expression compared to subgroup (a). ROC analysis shows it to be a good predictor of no-reflow (AUC= 0.88, sensitivity = 73.7, Specificity = 95.2) which is significantly superior to cTnT (AUC difference of 0.231, P= 0.0233). As well, it was superior to cTnT as a predictor of in-hospital MACE (AUC difference of 0.367, P= 0.0053). Conclusion: This study highlights the value of miR-208a as a diagnostic and prognostic marker in STEMI context. To the best of our knowledge, this is the first study to investigate the value of miR-208a in no-reflow and almost the second to investigate the role of any known miRNA in no-reflow. Although still far from clinical application due to long time needed for the assay, the future introduction of new fast nucleic acids assays could support its clinical application. The study points to a possible mechanism for no-reflow development that needs to be thoroughly investigated.
Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+ T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses
Authors: Monzr M. Al Malki, Miguel-Angel Perales, Dipenkumar Modi, Sumithira Vasu, Megan Nelson, Donna Bui, Sojung Kim, Ruipeng Wang, Emily Lu, Mathias Oelke, Han Myint, Juan C. Varela
Journal: Blood (2020)
Perivascular mesenchymal cells control adipose-tissue macrophage accrual in obesity
Authors: Bo Shan, Mengle Shao, Qianbin Zhang, Chelsea Hepler, Vivian A. Paschoal, Spencer D. Barnes, Lavanya Vishvanath, Yu A. An, Lin Jia, Venkat S. Malladi, Douglas W. Strand, Olga T. Gupta, Joel K. Elmquist, Dayoung Oh, Rana K. Gupta
Journal: Nature Metabolism (2020)
Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis
Authors: Kiyomi Morita, Koji Sasaki, Guillaume Richard-Carpentier, Marina Konopleva, Xuelin Huang, Nicholas J. Short, Nitin Jain, Farhad Ravandi, Bouthaina S. Dabaja, Naval Daver, Tapan M. Kadia, Yesid Alvarado, Courtney D. DiNardo, Ghayas C. Issa, Naveen Pemmaraju, Guillermo Garcia-Manero, Srdan Verstovsek, Sa A Wang, Joseph D. Khoury, Jeffrey L. Jorgensen, Richard E. Champlin, Issa F. Khouri, Partow Kebriaei, Heather M. Schroeder, Maria Khouri, Koichi Takahashi, Susan M. O'Brien, Hagop M. Kantarjian, Elias Jabbour
Journal: Blood (2020)
SAT0065 Meta-analysis of nsaid-induced gastrointestinal (gi) side effects in oa patients in japan
Authors: T Ochi, K Sugano, S Uemura, R Makuch
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> GI intolerance is one of the major causes of failure of NSAID treatment for arthritis patients. There has been a large number of studies to examine the risk of NSAID-induced GI side effects in US and Europe, but few studies in Japan. <h3>Objectives</h3> In order to evaluate the GI tolerability of NSAIDs in OA patients in Japan, a systematic review of Japanese randomised controlled trials was performed. <h3>Methods</h3> This meta-analysis consisted of double blind randomised controlled trials with 4-weeks NSAID treatment in OA patients in Japan. The analysis was composed of 25 trials with 26 types of NSAIDs, among which 6 types were used in more than two trials. The endpoints evaluated in the meta-analysis included incidence of any side effects, any digestive side effects and symptoms indicative of upper GI symptoms such as abdominal pain, nausea and dyspepsia. The general variance-based method was used to estimate the risk of these endpoints. Additionally, to evaluate the effect of risk factors for GI discomfort, odds ratios (ORs) of side effects by sex and age were estimated for individual treatment arms and then combined. <h3>Results</h3> The analysis included a total of 4,725 patients. On average, cumulative incidences of patients who had experienced any side effects and any digestive side effects were 14.3% (95% CI: 13.3–15.3%) and 10.4% (95% CI: 9.4–11.4%), respectively. Incidence of any side effects by type of NSAID were as follows: diclofenac 75 mg/day, 19.9% (10 trials), indomethacin 75 mg/day, 16.2% (12 trials), acemetacin 90 mg/day, 12.6% (2 trials), nabumetone 800 mg/day, 9.2% (2 trials), fenbufen 600 mg/day 8.8% (2 trials), and ibuprofen 900 mg/day, 7.8% (2 trials). Incidence of any digestive side effects were as follows: diclofenac, 16.6%, indomethacin, 10.2%, nabumetone, 8.3%, fenbfen, 6.9%, and ibuprofen 900 mg/day, 6.4%. Abdominal pain, nausea/vomiting and dyspepsia were the three most common digestive side effects. The cumulative incidence for the upper GI symptoms was estimated to be approximately 10.9%. Comparing the risk of upper GI symptoms between male and female, the summary OR was 1.71 (95% CI: 1.11- 2.65). Females were at significantly higher risk than males in the incidence of upper GI symptoms. Comparing the risk of upper GI symptoms between patients under 59 years and above 60 years old, the summary OR was 1.07 (95% CI: 0.75–1.52). <h3>Conclusion</h3> Despite the incidence of side effects varying across the different types of NSAIDs being used, there was an obvious increased risk of GI symptoms. Abdominal pain, nausea/vomiting and dyspepsia were the three most common GI discomforts and this trend is similar to the evidence in US and Europe. Females show a higher risk of side effects and are approximately 50% more likely to have side effects compared to males. Older patients tend to have a higher risk of side effects, but this is not statistically significant.
Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)
Authors: Tapan M. Kadia, Gautam Borthakur, Koichi Takahashi, Courtney D. DiNardo, Naval Daver, Naveen Pemmaraju, Elias Jabbour, Nitin Jain, Nicholas J. Short, Wei Qiao, Lade Adewale, Caitlin R. Rausch, Sherry A. Pierce, Yesid Alvarado, Amin M. Alousi, Uday R. Popat, Issa F. Khouri, Guillermo Garcia-Manero, Marina Konopleva, Jorge E. Cortes, Farhad Ravandi, Hagop M. Kantarjian
Journal: Blood (2020)
Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma
Authors: Matteo Claudio Da Via', Bachisio Ziccheddu, Matteo Dugo, Marta Lionetti, Katia Todoerti, Mattia D'Agostino, Antonino Neri, Luca Baldini, Paolo Corradini, Francesco Maura, Niccolo Bolli
Journal: Blood (2020)
Hyperuricemia and Musculoskeletal Complications in Thalassemia Patients
Authors: Juthatip Chaloemwong, Adisak Tantiworawit, Worawit Louthrenoo, Thanawat Rattanathammethee, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Ekarat Rattarittamrong, Lalita Norasetthada
Journal: Blood (2017)
Abstract PO-003: Bivalent histone modifications: Clinical targets against pancreatic cancer stem cell heterogeneity
Authors: Madhumita Das, Mayur Doke, Edwin Gonzalez, Daima Diaz, Bryan Pineda, Jonathan Celli, Marco Ruiz, Jayanta K. Das
Journal: Cancer Research (2020)

Abstract Bivalent histone modifications, the pre-transcriptional regulators were known as the chief orchestra underlining the mechanism of development for pancreatic cancer stem cells (PANCSCs) recently. The histone bivalency methylations are related to the transcriptional activation as well as repression of the prominent histone methylations (H3K4me3 and H3K27me3) at the transcript start sequence (TSS). These epigenetic changes are recognized to initiate heterogenic cancer stem cells (CSCs) reprogramming. Recent studies showed that the heterogenic CSCs are more resistant to anti-tumor drug therapy. Our previous study showed the relationship between bivalent histone modifications with the expression of pancreatic CSCs(CD44, CD24, CD133, Ep-CAM, ALDH1A3). Our current study is focused on the importance of designing anti-cancer drugs or epigenetic small molecules against bivalent histone modifications (to inhibit the upregulation of H3K4me3 or down-regulation of H3K27me3) related the expression of heterogenic pancreatic CSCs (CD44, CD24, CD133, Ep-CAM, ALDH1A3). The Cancer Stem Cells Therapeutic Target Database Version 2.0 (CSCTTv2.0) reported the high CD133 as PAN CSCs and high CD133, CD44 showed resistance to anticancer drugs (such as docetaxel, 5-FU, irinotecan, oxaliplatin) in many cancers. The Gemcitabine, a nucleoside analog, and Metformin are only drugs used for pancreatic cancer treatment and showed resistance against heterogenic PANCSCs. The biological informatics analyses (Cytoscape database, HPIDb, Spike, BioGrid, Reactome, MBInfo) were deployed in our study to find the effect of bivalent histone modifications on the TSS of the target genes in heterogenic PANCSCs and we found the effect at TSS of target genes CD44, and EZH2/ENX1. We also found a novel small molecule KY-02111 has an effect to reduce the expression of heterogenic PANCSCs at tumorigenic in vitro 3D spheroids model of PANC-1ORGR (Gemcitabine resistant) cells. Therefore, our preliminary study may give an important clue to find further the role of KY-02111 against the heterogenic pancreatic CSCs by inhibiting the upregulation of H3K4me3 or down-regulation of H3K27me3 as a clinical target for pancreatic cancer therapy. Citation Format: Madhumita Das, Mayur Doke, Edwin Gonzalez, Daima Diaz, Bryan Pineda, Jonathan Celli, Marco Ruiz, Jayanta K. Das. Bivalent histone modifications: Clinical targets against pancreatic cancer stem cell heterogeneity [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-003.
Single-Cell Transcriptomics of Human <i>TET2</i> Knockout CD4 T-Cells and Their Clonal Evolution
Authors: Yuping Li, Xiaoqian Liu, Xuxiang Liu, Xiwei Wu, Alyssa Bouska, Waseem G. Lone, Chan-Wang J. Lio, Tyler Herek, Logan Lee, Gehong Dong, Jinhui Wang, Chih-Hong Lou, Wei Qi, Kunal Shetty, Timothy W. McKeithan, Javeed Iqbal, Wing (John) C. Chan
Journal: Blood (2020)
Five thousand years of minimal access surgery: 3000BC to 1850: early instruments for viewing body cavities
Authors: Rachel Hargest
Journal: Journal of the Royal Society of Medicine (2020)

Summary Surgeons and their patients recognise that one of the major advances in surgical technique over the last 20 years has been the growth of minimal access surgery by means of laparoscopic and robotic approaches. Partnerships with industry have facilitated the development of advanced technical instruments, light sources, recording devices and optics which are almost out of date by the time they are introduced to surgical practice. However, lest we think that technological innovation is entirely a modern concept, we should remember that our predecessors were masters of their craft and able to apply new technologies to surgical practice. The history of minimal access surgery can be traced back to approximately 5000 years ago and this review aims to remind us of the achievements of historical doctors and engineers, as well as bring more modern developments to wider attention. This review will comprise a three-part series: Part I 3000BC to 1850 Early instruments for viewing body cavities Part II 1850 to 1990 Technological developments Part III 1990 to present Organisational issues and the rise of the robots
AB0377 COMPUTATIONAL DISCOVERY AND PRECLINICAL VALIDATION OF THERAPEUTIC LEADS WITH NOVEL MOAS FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Authors: I. Hakim, S. Mujahid, A. C. Daugherty, T. S. Heuer
Journal: Annals of the Rheumatic Diseases (2020)

Background: Lupus is a heterogeneous, systemic disease that affects millions of patients globally with a high unmet medical need. We present results from our powerful and efficient computational drug discovery platform that identifies hits with first-in-class mechanisms of action that can advance rapidly and successfully through preclinical validation studies. The twoXAR discovery platform uses an artificial-intelligence framework to integrate diverse patient-derived biomedical data sets to build holistic and unbiased models of human disease biology. The utilization of diverse, proprietary algorithms and deep learning principles provides a highly sensitive platform to elucidate complex disease-specific associations between biology and biomedical data that are integrated with a library of existing drug molecules. This enables the identification of novel, high-value drug discovery hits with known pharmacological properties. The twoXAR platform also preserves interpretable data-driven links to disease biology to facilitate efficient validation and optimization studies. Objectives: Apply twoXAR’s computational drug discovery platform for the discovery of first-in-class lupus therapy hits and perform preclinical characterization of selected hits to identify drug discovery lead molecules. Methods: Using clinical SLE patient data, we employed the twoXAR platform to build an in-silico SLE disease model. Nine molecules with novel mechanisms of action (not previously tested as candidate clinical therapies for lupus) were identified as drug discovery hits and then characterized in preclinical efficacy studies using the MRL mouse model of lupus. Results: In preclinical validation studies with the MRL mouse model, 2 compounds were differentiated by significant efficacy and excellent tolerability. TXR-711 and TXR-712 increased renal function, decreased renal inflammation and decreased inflammation compared to vehicle-treated control mice. In particular, TXR-711 and TXR-712 significantly decreased serum blood urea nitrogen (BUN) levels, decreased proteinuria levels, and significantly improved kidney histology readouts such as glomerulonephritis and tubule basophilia. Additionally, TXR-711 and TXR-712 treatment resulted in significantly decreased inguinal lymph node weight. Conclusion: TXR-711 and TXR-712 were identified as SLE drug discovery leads with novel MOAs for further preclinical development. Ongoing studies with TXR-711 and TXR-712 includes pharmacokinetic, pharmacodynamic, and additional MRL mouse efficacy characterization. Disclosure of Interests: Isaac Hakim Employee of: twoXAR, Inc, Sana Mujahid Employee of: twoXAR, Inc., Aaron C. Daugherty Employee of: twoXAR, Inc., Timothy S. Heuer Employee of: twoXAR, Inc
Efficacy and Safety of Baricitinib in Refractory Chronic Graft-Versus-Host Disease (cGVHD): Preliminary Analysis Results of a Phase 1/2 Study
Authors: Noa G. Holtzman, Annie Im, Alen Ostojic, Lauren M. Curtis, Laura Parsons-Wandell, Jeannette Nashed, Cody Peer, William D. Figg, M. Teresa Magone, Edward W Cowen, Jacqueline W Mays, Frances T. Hakim, Jeremy J. Rose, Marie C Pouzelles, Naomi Taylor, Steven Z. Pavletic
Journal: Blood (2020)
Carcinogenicity of some aromatic amines and related compounds
Authors: David M. DeMarini, Tania Carreón-Valencia, William M. Gwinn, Nancy B. Hopf, Martha S. Sandy, Tina Bahadori, Gloria M. Calaf, Guosheng Chen, Aline de Conti, Lin Fritschi, Min Gi, P. David Josephy, Jorunn Kirkeleit, Kristina Kjaerheim, Sophie Langouët, Damien M. McElvenny, Consolato M. Sergi, Leslie T. Stayner, Takeshi Toyoda, Yann Grosse, Lamia Benbrahim-Tallaa, Fatiha El Ghissassi, Eero Suonio, Michelle C. Turner, Ian A. Cree, Heidi Mattock, Karen Müller, Felicia Chung, Kathryn Z. Guyton, Mary K. Schubauer-Berigan
Journal: The Lancet Oncology (2020)
A Report of Fourcases of Severethrombocytopenia with Rh G-CSF Mobilized Allogeneic Peripheral Blood Stem Cell Transplant Donors
Authors: Qingzhen Liu, Jianfeng Yao, Donglin Yang, Aiming Pang, Erlie Jiang, Sizhou Feng, Ming-Zhe Han
Journal: Blood (2020)
Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies
Authors: Dimitrios A. Tsakiris, Johannes Oldenburg, Robert Klamroth, Benoît Guillet, Kate Khair, Angela Huth-Kühne, Karin Kurnik, Stephan Regensburger, Jaco Botha, Alejandro Fernandez, Leilei Tang, Margareth C. Ozelo
Journal: Blood (2020)